NCT01251770

Brief Summary

The primary objective of this study is to compare the blood sodium level after 12 hours following the initiation of therapy with either 0.3% NaCl/dextrose 5% or 0.45% NaCl/dextrose 5%, in postsurgical hospitalized children requiring maintenance IV fluid administration.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Dec 2010

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2010

Completed
1 day until next milestone

Study Start

First participant enrolled

December 1, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 2, 2010

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
7 months until next milestone

Results Posted

Study results publicly available

January 25, 2012

Completed
Last Updated

March 3, 2017

Status Verified

January 1, 2017

Enrollment Period

7 months

First QC Date

November 30, 2010

Results QC Date

December 13, 2011

Last Update Submit

January 17, 2017

Conditions

Keywords

HyponatremiaWater-Electrolyte Imbalance

Outcome Measures

Primary Outcomes (1)

  • Change in Sodium Levels

    Change from baseline in sodium level after 12 hours

Secondary Outcomes (1)

  • IV Fluid Intake

    12 hours from baseline

Study Arms (2)

half saline

EXPERIMENTAL

Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.

Drug: 0.45% NaCl/dextrose 5%

third saline

ACTIVE COMPARATOR

Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.

Drug: 0.3% NaCl/dextrose 5%

Interventions

Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.

Also known as: half saline
half saline

Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.

Also known as: third saline
third saline

Eligibility Criteria

Age1 Month - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Postsurgical children admitted to HGNPE Department of Surgery between january 2010 and october 2011.
  • Aged 1 month to 16 years. Initial plasma Na between 135-145 mmol/L. Primary route of fluid administration is anticipated to be intravenous, in the first 12 hours following surgery.
  • Informed consent of parent/guardian.

You may not qualify if:

  • Children with illness that have primary fluid and electrolyte imbalance such as:
  • Shock: Defined as acute circulatory failure resulting in decreased tissue perfusion and manifesting as altered sensorium, hypothermia (\<35oC), tachycardia, prolonged capillary filling time (\>3 seconds), hypotension (BP \< 5th percentile for age), oliguria (\<0.5 ml/kg/hr), hypoxemia, hyperlactatemia, requirement of fluid bolus and/ or vasopressors.
  • Diarrhea and Dehydration: Children presenting with diarrhea and features of dehydration: lethargy, irritability and altered sensorium, thirst, decreased urine output, sunken eyes \& dry mucous membranes, loss of skin elasticity.; children with ongoing diarrhea will be excluded even if there is no dehydration.
  • Fluid Overload: Cirrhosis, Congestive heart failure, Acute and Chronic renal failure, Nephrotic syndrome.
  • Hyperglycemia: blood glucose \> 180 mg/ dl.
  • Require ICU admission.
  • Severe Protein Energy Malnutrition: Defined as grade III (50-59% of expected weight for age) and grade IV (less than 50% of expected weight for age) as per IAP classification.
  • Patients in whom either hypotonic or isotonic solutions may be contraindicated/necessary: i.e. specific neurosurgical patients (ie those at risk of increased ICP, e.g. requiring actual brain surgery, ICP monitor or external ventricular drain insertion), patients with diabetic ketoacidosis, acute (≤ 7 days) burns, pre-existing CHF, liver failure or cirrhosis, renal failure.
  • Patients with known pre-existing risk of PNa derangements: DI or SIADH

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Niños Pedro de Elizalde

Buenos Aires, Buenos Aires F.D., C1270AAN, Argentina

Location

Related Publications (3)

  • Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child. 2006 Oct;91(10):828-35. doi: 10.1136/adc.2005.088690. Epub 2006 Jun 5.

    PMID: 16754657BACKGROUND
  • Neville KA, Sandeman DJ, Rubinstein A, Henry GM, McGlynn M, Walker JL. Prevention of hyponatremia during maintenance intravenous fluid administration: a prospective randomized study of fluid type versus fluid rate. J Pediatr. 2010 Feb;156(2):313-9.e1-2. doi: 10.1016/j.jpeds.2009.07.059. Epub 2009 Oct 9.

    PMID: 19818450BACKGROUND
  • Yung M, Keeley S. Randomised controlled trial of intravenous maintenance fluids. J Paediatr Child Health. 2009 Jan-Feb;45(1-2):9-14. doi: 10.1111/j.1440-1754.2007.01254.x. Epub 2007 Nov 25.

    PMID: 18036144BACKGROUND

Related Links

MeSH Terms

Conditions

HyponatremiaWater-Electrolyte Imbalance

Condition Hierarchy (Ancestors)

Metabolic DiseasesNutritional and Metabolic Diseases

Results Point of Contact

Title
Dr Facundo Jorro Barón
Organization
Hospital General de Niños Pedro de Elizalde

Study Officials

  • Manuela Dicembrino, md

    Hospital de Niños Pedro de Elizalde

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2010

First Posted

December 2, 2010

Study Start

December 1, 2010

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

March 3, 2017

Results First Posted

January 25, 2012

Record last verified: 2017-01

Locations